Tempest Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Tempest Therapeutics, Inc. (TPST) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$5.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-13
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$5.24M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$27.70M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$4.02M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$3.51M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$26.26M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$41.84M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$29.49M.
- Tempest Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$35.71M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.24M 10-Q · filed 2026-08-13 | -$32.94M 10-Q · filed 2026-08-13 | -$36.96M derived: sum of 3 quarters · filed 2026-08-13 | -$40.47M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$27.70M 10-Q · filed 2026-05-14 | -$31.72M derived: sum of 2 quarters · filed 2026-05-14 | -$35.23M derived: sum of 3 quarters · filed 2026-05-14 | -$43.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$7.53M derived: sum of 2 quarters · filed 2026-03-30 | -$15.40M derived: sum of 3 quarters · filed 2026-08-13 | -$26.26M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$3.51M 10-Q · filed 2025-11-05 | -$11.38M derived: sum of 2 quarters · filed 2026-08-13 | -$22.24M 10-Q · filed 2025-11-05 | -$36.05M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$7.87M 10-Q · filed 2026-08-13 | -$18.73M 10-Q · filed 2026-08-13 | -$32.54M derived: sum of 3 quarters · filed 2026-08-13 | -$43.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$10.86M 10-Q · filed 2026-05-14 | -$24.67M derived: sum of 2 quarters · filed 2026-05-14 | -$35.23M derived: sum of 3 quarters · filed 2026-05-14 | -$44.80M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$24.37M derived: sum of 2 quarters · filed 2026-03-30 | -$33.94M derived: sum of 3 quarters · filed 2026-03-30 | -$41.84M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | -$10.56M 10-Q · filed 2025-11-05 | -$20.13M derived: sum of 2 quarters · filed 2025-11-05 | -$28.03M 10-Q · filed 2025-11-05 | -$35.52M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$9.57M 10-Q · filed 2025-08-11 | -$17.47M 10-Q · filed 2025-08-11 | -$24.96M derived: sum of 3 quarters · filed 2025-08-11 | -$31.75M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | -$7.90M 10-Q · filed 2025-05-13 | -$15.39M derived: sum of 2 quarters · filed 2025-05-13 | -$22.18M derived: sum of 3 quarters · filed 2025-05-13 | -$29.76M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$7.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$14.27M derived: sum of 2 quarters · filed 2025-03-27 | -$21.86M derived: sum of 3 quarters · filed 2025-03-27 | -$29.49M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$6.79M 10-Q · filed 2024-11-12 | -$14.37M derived: sum of 2 quarters · filed 2024-11-12 | -$22.00M 10-Q · filed 2024-11-12 | -$31.11M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$7.58M 10-Q · filed 2024-08-08 | -$15.22M 10-Q · filed 2024-08-08 | -$24.32M derived: sum of 3 quarters · filed 2024-08-08 | -$33.27M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$7.64M 10-Q · filed 2024-05-09 | -$16.74M derived: sum of 2 quarters · filed 2024-05-09 | -$25.69M derived: sum of 3 quarters · filed 2024-05-09 | -$34.85M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$18.05M derived: sum of 2 quarters · filed 2024-03-19 | -$27.22M derived: sum of 3 quarters · filed 2024-03-19 | -$35.71M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | -$8.95M 10-Q · filed 2023-11-08 | -$18.11M derived: sum of 2 quarters · filed 2023-11-08 | -$26.61M 10-Q · filed 2023-11-08 | -$34.38M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$9.17M 10-Q · filed 2023-08-10 | -$17.66M 10-Q · filed 2023-08-10 | -$25.44M derived: sum of 3 quarters · filed 2023-08-10 | -$33.55M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$8.49M 10-Q · filed 2023-05-10 | -$16.27M derived: sum of 2 quarters · filed 2023-05-10 | -$24.38M derived: sum of 3 quarters · filed 2023-05-10 | -$31.44M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$7.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$15.89M derived: sum of 2 quarters · filed 2023-03-22 | -$22.95M derived: sum of 3 quarters · filed 2023-03-22 | -$28.30M 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | -$8.11M 10-Q · filed 2022-11-08 | -$15.17M derived: sum of 2 quarters · filed 2022-11-08 | -$20.52M 10-Q · filed 2022-11-08 | -$24.84M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$7.06M 10-Q · filed 2022-08-15 | -$12.41M 10-Q · filed 2022-08-15 | -$16.73M derived: sum of 3 quarters · filed 2022-08-15 | -$22.16M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$5.36M 10-Q · filed 2022-05-13 | -$8.39M 10-Q · filed 2021-05-13 | -$9.68M derived: sum of 2 quarters · filed 2022-05-13 | -$15.11M derived: sum of 3 quarters · filed 2022-05-13 | -$20.34M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | -$4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$9.75M derived: sum of 2 quarters · filed 2022-03-29 | -$14.98M derived: sum of 3 quarters · filed 2022-03-29 | -$19.21M 10-K · filed 2022-03-29 | -$36.41M 10-K · filed 2021-03-29 | |||
| 2020-09-30 | -$5.43M 10-Q · filed 2021-11-10 | -$6.37M 10-Q · filed 2020-11-09 | -$10.66M derived: sum of 2 quarters · filed 2021-11-10 | -$14.89M 10-Q · filed 2021-11-10 | -$29.04M 10-Q · filed 2020-11-09 | -$35.36M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | -$5.23M 10-Q · filed 2021-08-12 | -$10.67M 10-Q · filed 2020-08-10 | -$9.46M 10-Q · filed 2021-08-12 | -$22.67M 10-Q · filed 2020-08-10 | -$29.93M derived: sum of 3 quarters · filed 2021-08-12 | -$41.56M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$12.00M 10-Q · filed 2021-05-13 | -$24.70M derived: sum of 2 quarters · filed 2021-05-13 | -$36.33M derived: sum of 3 quarters · filed 2021-05-13 | -$46.20M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | -$12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$24.33M derived: sum of 2 quarters · filed 2021-03-29 | -$34.20M derived: sum of 3 quarters · filed 2021-03-29 | -$44.57M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | -$11.63M 10-Q · filed 2020-11-09 | -$21.50M derived: sum of 2 quarters · filed 2020-11-09 | -$31.87M 10-Q · filed 2020-11-09 | -$41.73M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | -$9.87M 10-Q · filed 2020-08-10 | -$20.24M 10-Q · filed 2020-08-10 | -$30.09M derived: sum of 3 quarters · filed 2020-08-10 | -$37.99M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | -$10.37M 10-Q · filed 2020-05-08 | -$20.22M derived: sum of 2 quarters · filed 2020-05-08 | -$28.11M derived: sum of 3 quarters · filed 2020-05-08 | -$33.16M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | -$9.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$17.75M derived: sum of 2 quarters · filed 2020-03-11 | -$22.79M derived: sum of 3 quarters · filed 2020-03-11 | -$27.18M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$7.89M 10-Q · filed 2019-11-13 | -$12.93M derived: sum of 2 quarters · filed 2019-11-13 | -$17.32M 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | -$5.04M 10-Q · filed 2019-08-12 | -$9.43M 10-Q · filed 2019-08-12 | ||||||
| 2018-03-31 | -$4.39M 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | -$84.59M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |